In a major breakthrough for affordable oncology care, Pinnacle Life Science Pvt. Ltd., a subsidiary of Aarti Drugs, has officially launched Venetoclax in India. With this milestone, Pinnacle becomes the first and only generic manufacturer to bring this critical blood cancer treatment to the Indian market.
Venetoclax is a vital, life-saving molecule for patients battling blood cancer. Historically, the treatment was out of reach for the vast majority of Indian families due to high innovator pricing. Recognizing this critical gap, Pinnacle partnered with key industry players to bring a generic alternative to market at just a quarter of the original cost effectively reducing the financial burden by 75%.
The company assures that the significant price drop does not compromise quality, as the drug is manufactured to meet the highest international regulatory standards. Vishwa Savla, representing Pinnacle, noted that the launch directly reflects the company’s core mission: ensuring that access to life-saving medical care is determined by patient need rather than financial capacity. This landmark release is set to dramatically improve treatment accessibility and outcomes for cancer patients nationwide.
Written by: Pragna Biswas
Graphics by: Pramit Hazra
